scispace - formally typeset
M

Mitzi Nagarkatti

Researcher at University of South Carolina

Publications -  363
Citations -  14950

Mitzi Nagarkatti is an academic researcher from University of South Carolina. The author has contributed to research in topics: Immune system & Inflammation. The author has an hindex of 59, co-authored 332 publications receiving 12105 citations. Previous affiliations of Mitzi Nagarkatti include Veterans Health Administration & Virginia Tech.

Papers
More filters
Journal Article

Role of cytokines as a double-edged sword in sepsis.

TL;DR: A decrease in IL-6 was associated with a better prognosis and overproduction of IL-10 was found to be the main predictor of severity and fatal outcome, indicating pro-inflammatory and anti-inflammatory cytokines constitute a double-edged sword in sepsis.
Journal ArticleDOI

Cannabinoids as novel anti-inflammatory drugs

TL;DR: This review will focus on the potential use of cannabinoids as a new class of anti-inflammatory agents against a number of inflammatory and autoimmune diseases that are primarily triggered by activated T cells or other cellular immune components.
Journal ArticleDOI

Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease

TL;DR: The current data demonstrate that CB2 cannabinoid receptors expressed on malignancies of the immune system may serve as potential targets for the induction of apoptosis, and because CB2 agonists lack psychotropic effects, they may Serve as novel anticancer agents to selectively target and kill tumors of immune origin.
Journal ArticleDOI

Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis.

TL;DR: These studies demonstrate for the first time that AhR activation promotes epigenetic regulation thereby influencing reciprocal differentiation of Tregs and Th17 cells, and amelioration of inflammation.
Journal ArticleDOI

Macromolecular-clustered facial amphiphilic antimicrobials.

TL;DR: It is shown that cholic acid derivatives with three charged head groups are more potent and selective than lithocholic and deoxycholic counterparts, particularly against Gram-negative bacteria.